A US biotechnology-based pharmaceutical company focused on the development and commercialization of novel cancer therapies has appointed Aagami to seek companies in South Korea who would like to in-license their novel therapeuic vaccine platform.

The client's Novel therapeutic vaccine targeting the tumor endothelium, is a clinic-ready IND filed candidate for non-small cell lung cancer (NSCLC).

Aagami CEO Dinesh Jain will visit Seoul in South Korea in December 2016 to attend the Korea Drug Development Fund Techfair, and will be meeting several Bio Pharma companies to promote strategic partnerships for the client Aagami CEO is also one of the speakers during KDDF Techfair 2016 and will be showcasing client's asset in an audience of more than 200 industry professionals and decision makers.